Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|February 5, 2003
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancerC Dittrich, B Coudert, L Paz-Ares, et al.
British Journal of Cancer|September 17, 2009
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinomaF Végran, R Boidot, B Coudert, et al.
European Journal of Clinical Pharmacology|July 10, 2021
Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancerA Petitcollin, N Azzopardi, J Y Pierga, et al.
British Heart Journal|January 1, 1995
Impairment of diastolic function during short-term anthracycline chemotherapyY Cottin, C Touzery, B Coudert, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 4, 2001
Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot studyN Isambert, M Correia, J P Cercueil, et al.
Bulletin Du Cancer|October 1, 1996
[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin]B Coudert, C De Gislain, J L Beltramo, et al.
European Journal of Cancer Care|May 8, 2013
Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based studyT S Dabakuyo, A Arnaud, P Maingon, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 23, 2020
Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancerC-G Kaderbhaï, B Coudert, A Bertaut, et al.
British Journal of Cancer|October 28, 2010
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancerS Guiu, M Gauthier, B Coudert, et al.
Annales De Biologie Clinique|April 9, 2002
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]J M Riedinger, N Eche, J P Basuyau, et al.
Pageof 7